What were the results of the ROCKET AF trial?
The ROCKET AF trial found that Rivaroxaban was non-inferior to Warfarin in terms of its effectiveness in preventing ischemic and hemorrhagic stroke and systemic embolism in patients with nonvalvular atrial fibrillation, with a reduced rate of major or non-major bleeding compared to Warfarin. Subsequent subgroup analyses also found that Rivaroxaban had borderline superiority to Warfarin in intention-to-treat analysis of efficacy, and no differences in effectiveness according to age, sex, CHADS2 score, or the presence of moderate renal insufficiency.